Product Name: Human PCSK9 Antibody (Ralpancizumab, Research Use)
Catalog Number: NBR-0827
Target Name: PCSK9
Trade Name: Ralpancizumab
Antibody Drug Description: Ralpancizumab (development code RN317, or PF-05335810) is a monoclonal antibody (mAb) designed for the treatment of dyslipidemia. It was developed by Pfizer. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: PCSK9
Synonyms: FH3; HCHOLA3; NARC-1
Target Description: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments.
Ensembl: ENSG00000169174
Uniprot: Q8NBP7